Share information
252.30 €
+1.57 %
27/02/2026 17:37
+1.57 %
Open
High
Low
Volume
248.40 €
255.60 €
247.80 €
615,729
Latest News
26-Feb-2026
Strong Execution Fueling Sustained Company Growth
04-Feb-2026
UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements
30-Jan-2026
KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)
13-Jan-2026
Innovation and Execution Power UCB’s Success